Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Phase 2

Active, not recruiting

Conditions: Recurrent Chronic Lymphocytic Leukemia
Recurrent Grade 1 Follicular Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Plasma Cell Myeloma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Grade 3a Follicular Lymphoma

Interventions: Biological: Nivolumab

First Posted Date: 2019-12-19

Last Posted Date: 2024-10-17

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT04205409

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Use of Virtual Reality for Pelvic External Fixator Removal

Not Applicable

Conditions: Pelvic Fracture Pubic Rami Multiple - Unstable Closed

Interventions: Other: Virtual Reality

First Posted Date: 2019-12-17

Last Posted Date: 2019-12-17

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT04202315

Locations: 🇺🇸
University of Washington/Harborview Medical Center, Seattle, Washington, United States

Iterative Redesign of a Behavioral Skills Training Program for Use in Educational Settings

Completed

Conditions: Autism Spectrum Disorder
Disruptive Behavior

Interventions: Behavioral: RUBIES
Behavioral: RUBI

First Posted Date: 2019-12-16

Last Posted Date: 2022-05-20

Lead Sponsor: University of Washington

Target Recruit Count: 40

Registration Number: NCT04199533

Locations: 🇺🇸
Seattle Public Schools, Seattle, Washington, United States

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Phase 1

Terminated

Conditions: Refractory Acute Myeloid Leukemia
Myeloid Neoplasm
Recurrent Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Mitoxantrone

First Posted Date: 2019-12-12

Last Posted Date: 2023-12-28

Lead Sponsor: University of Washington

Target Recruit Count: 13

Registration Number: NCT04196010

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Addressing Microaggressions in Racially Charged Patient-provider Interactions: A Pilot Randomized Trial

Not Applicable

Completed

Conditions: Racism

Interventions: Other: Bias-reduction Intervention

First Posted Date: 2019-11-29

Last Posted Date: 2019-12-03

Lead Sponsor: University of Washington

Target Recruit Count: 25

Registration Number: NCT04180956

Locations: 🇺🇸
Bastyr University Seattle Clinic, Seattle, Washington, United States

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Phase 2

Recruiting

Conditions: Prostate Adenocarcinoma

Interventions: Procedure: Positron Emission Tomography
Procedure: Lymphadenectomy
Drug: Abiraterone Acetate
Procedure: Computed Tomography
Radiation: Radiation Therapy
Procedure: PSMA PET Scan
Drug: Prednisone
Drug: Abiraterone

First Posted Date: 2019-11-25

Last Posted Date: 2024-12-30

Lead Sponsor: University of Washington

Target Recruit Count: 100

Registration Number: NCT04175431

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Phase 1

Terminated

Conditions: Recurrent Follicular Lymphoma
Grade 3b Follicular Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma

Interventions: Drug: Copanlisib
Drug: Gemcitabine
Drug: Carboplatin
Drug: Dexamethasone
Biological: Rituximab
Biological: Pegfilgrastim

First Posted Date: 2019-11-08

Last Posted Date: 2023-06-29

Lead Sponsor: University of Washington

Target Recruit Count: 12

Registration Number: NCT04156828

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Terminated

Conditions: Lymphoid Leukemia
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Copanlisib
Biological: Rituximab
Drug: Bendamustine

First Posted Date: 2019-11-07

Last Posted Date: 2022-04-11

Lead Sponsor: University of Washington

Target Recruit Count: 1

Registration Number: NCT04155840

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Addiction Treatment Outcome Monitoring Study

Not Applicable

Completed

Conditions: Alcohol Use Disorder
Substance Use Disorders

Interventions: Other: Measurement
Other: Feedback

First Posted Date: 2019-11-07

Last Posted Date: 2022-05-20

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT04155385

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

Not Applicable

Recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Drug: Chemotherapy
Biological: Immunotherapy
Radiation: Radiation Therapy

First Posted Date: 2019-11-05

Last Posted Date: 2025-06-05

Lead Sponsor: University of Washington

Target Recruit Count: 80

Registration Number: NCT04151940

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy